Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
Abingdon Health PLC (AIM:ABDX) AppDx ® lateral flow smartphone reader granted further patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
Abingdon Health PLC (AIM:ABDX) Trading Update
York, U.K. 28 February 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), provides its half-year trading update for the six months
Abingdon Health PLC (AIM:ABDX) Award of Options under new LTIP Scheme
York, U.K. 19 December 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces the establishment of a new Long Term Incentive Plan
Abingdon Health PLC (AIM:ABDX) Preliminary Results
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces its preliminary results for the year ended
Abingdon Health PLC (AIM:ABDX) Further re. Outcome of Judicial Review
All grounds were dismissed, including the claim of state aid, apparent bias and national preference
Abingdon Health PLC (AIM:ABDX) Outcome of Judicial Review – All claims brought by GLP dismissed
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, notes the judgement by Mr Justice Waksman in
Abingdon Health PLC (AIM:ABDX) Judicial Review – judgement expected
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high-quality and effective rapid tests, notes that a judgement in relation to the
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery.
Tiziana Life Sciences Announces Positive Clinical Results
In the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab.
Abingdon Health PLC (AIM:ABDX) Supply agreement for Abingdon COVID-19 tests
Purchase of 10m Abingdon Health Simply Test COVID-19 antigen tests; subject to Taiwan FDA approval of test